1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-149816
    Anti-inflammatory agent 41 Inhibitor
    Anti-inflammatory agent 41 (13a) 显著抑制脂多糖(LPS)诱导的J774A.1、THP-1和LX-2细胞中促炎细胞因子IL-6和TNF-α的表达,并抑制了NF-κB通路的激活。
    Anti-inflammatory agent 41
  • HY-P991063
    GEN-1053 Inhibitor
    GEN-1053 (BNT-313)是一种人源化的 IgG1 抗体,靶向 CD27。GEN-1053 与 CD27 结合并在结合后形成六聚体。GEN-1053 的同型对照可参考 Human IgG1 lambda1, Isotype Control (HY-P99992)。
    GEN-1053
  • HY-157147
    NLRP3-IN-24
    NLRP3-IN-24 (化合物 15a) 是针对 NLRP3 的抑制剂。NLRP3-IN-24 对 NLRP3 炎症小体的激活具有抑制作用。
    NLRP3-IN-24
  • HY-168971
    Paeoniflorin-6′-O-benzene sulfonate Antagonist
    Paeoniflorin-6′-O-benzene sulfonate (CP-25) 是 G 蛋白偶联受体激酶 2 (GRK2) 的抑制剂,可抑制 GRK2 易位至细胞膜,抑制 JAK1/STAT3 信号通路。Paeoniflorin-6′-O-benzene sulfonate 可抑制 IL-17A/CXCL2 诱导的 HaCaT 增殖。Paeoniflorin-6′-O-benzene sulfonate 在小鼠模型中降低 IL-17A、IL-17F、IFN-γ、TNF-α、IL-22、IL-23、CXCL2、CXCL3 和 CXCL9 等炎症因子和趋化因子的水平,减轻 Imiquimod (HY-B0180) 诱导的银屑病。
    Paeoniflorin-6′-O-benzene sulfonate
  • HY-N0722R
    Neochlorogenic acid (Standard)

    新绿原酸 (Standard)

    Inhibitor
    Neochlorogenic acid (Standard) 是 Neochlorogenic acid 的分析标准品。本产品用于研究及分析应用。Neochlorogenic acid 是在干果和其他植物中发现的一种天然多酚化合物。Neochlorogenic acid 抑制 TNF-αIL-1β 产生。Neochlorogenic acid 抑制 iNOSCOX-2 蛋白表达。Neochlorogenic acid 还抑制磷酸化的 NF-κB p65p38 MAPK 活化。
    Neochlorogenic acid (Standard)
  • HY-128754R
    Monoolein (Standard) Inhibitor
    Monoolein 是一种具有生物相容性的脂质分子,可作为载体用于骨修复。Monoolein 具有抗炎活性,可抑制 LPS (HY-D1056) 诱导的免疫反应。Monoolein 通过减少免疫反应因子 (如 IL-12 p40, IL-6, 和 TNF-α) 的产生,并抑制 NO 的生成,来发挥抗炎作用。Monoolein 可用于药物递送和炎症疾病领域的研究。
    Monoolein (Standard)
  • HY-169731
    RO27-3225 trifluoroacetate Inhibitor
    RO27-3225 trifluoroacetate 是黑素皮质素受体 4 (MC4R) 的肽激动剂,具有神经保护和抗炎活性,EC50 值为 1 nM,而 MC1R 为 8 nM。RO27-3225 trifluoroacetate 在失血性休克和复苏大鼠腹腔高压模型中逆转失血性休克,降低脑水肿、血脑屏障 (BBB) 通透性和海马 IL-1β 和 TNF-α 水平。
    RO27-3225 trifluoroacetate
  • HY-172608
    TNF-α-IN-24 Inhibitor
    TNF-α-IN-24 (Example 15) 是一种 TNF-α 抑制剂,IC50 值为 4.1 nM。TNF-α-IN-24 可用于类风湿关节炎、克罗恩病等炎症性及自身免疫性疾病的研究。
    TNF-α-IN-24
  • HY-P991513
    BI-655064 Inhibitor
    BI-655064 是一种人源化抗 CD40 抗体,其可结晶片段 (Fc) 区发生两处突变,可阻止 Fc 介导的抗体依赖性或补体介导的细胞毒性和血小板活化。BI-655064 可用于研究自身免疫性疾病,例如狼疮性肾炎和类风湿性关节炎 (RA)。
    BI-655064
  • HY-171780
    ASP9831 Inhibitor
    ASP9831 是一种具有口服活性的 PDE4 抑制剂。ASP9831 可抑制 LSP 诱导的 TNF-α 的产生,具有抗炎活性。ASP9831 可用于脂肪肝炎的研究。
    ASP9831
  • HY-N15519
    Crocatin B Inhibitor
    Crocatin B 可在 P. crocatum Ruiz & Pav 中发现。Crocatin B 可通过抑制 TNF-αICAM-1 的表达发挥抗炎活性。Crocatin B 具有抗肿瘤活性。
    Crocatin B
  • HY-P991440
    AMG-966 Inhibitor
    AMG-966 是一种靶向 TNFSF15/TL1A & TNFα 的人类双特异性抗体 (bsAb)。AMG 966 可恢复无糖基化 Fc 结构域结合 FcγRIa 和 FcγRIIa 的能力,从而导致抗药抗体 (ADA) 的形成。AMG 966 可用于克罗恩病和溃疡性结肠炎的研究。推荐同型对照:Human IgG1 kappa,Isotype Control (HY-P99001)。
    AMG-966
  • HY-P10693
    CZEN-002 Inhibitor
    CZEN-002 是 α-促黑素细胞激素衍生物,具有抗炎和抗菌活性,抑制 TNF-α 的产生。
    CZEN-002
  • HY-N7699A
    D-Trimannuronic acid

    D-甘露糖醛酸三糖

    Activator
    D-Trimannuronic acid 是一种从海藻中提取的藻酸盐低聚物,可以诱导小鼠巨噬细胞分泌 TNF-α。D-Trimannuronic acid 可用于疼痛和血管性痴呆的研究。
    D-Trimannuronic acid
  • HY-119866
    β-Alethine
    β-Alethine 是一种二硫化物,可用作抗肿瘤剂和免疫佐剂。
    β-Alethine
  • HY-107352R
    Fosfenopril (Standard)

    福辛普利拉EP杂质A) (Standard)

    Inhibitor
    Fosfenopril (Standard)是 Fosfenopril 的分析标准品。本产品用于研究及分析应用。Fosfenopril (Fosinoprilat) 是一种有效的血管紧张素转换酶 (ACE) 抑制剂。Fosfenopril 通过抑制单核细胞中 TLR4/NF-κB 信号通路缓解脂多糖 (LPS) 诱导的炎症反应。
    Fosfenopril (Standard)
  • HY-P991525
    2141-V11 Agonist
    2141-V11 是一种抗 CD40 激动剂抗体,与 FcγRIIB 结合增强。2141-V11 在体内可引发有效的肿瘤特异性 T 细胞应答。2141-V11 可用于研究 BCG 无反应性非肌层浸润性膀胱癌。
    2141-V11
  • HY-P99820
    Ranevetmab
    Ranevetmab (NV-01) 是一种犬源化的抗 NGF 单克隆抗体 (mAb)。Ranevetmab 可减轻疼痛,用于退行性关节病 (DJD) 疼痛的研究。
    Ranevetmab
  • HY-P991455
    PTX-35 Agonist
    PTX-35 是一种靶向 TNFRSF25 的人类 IgG 单克隆抗体 (mAb)。PTX-35 在小鼠黑色素瘤模型中,可降低调节性 T 细胞的抑制活性并增强 CD4+ T 细胞效应反应。PTX-35 可用于胰岛细胞移植排斥和实体瘤的研究。推荐同型对照:Human IgG1 kappa,Isotype Control (HY-P99001)。
    PTX-35
  • HY-P990526
    Anti-TNFRSF21/DR6/CD358 Antibody Inhibitor
    Anti-TNFRSF21/DR6/CD358 Antibody 是 CHO 表达的人源化抗体,靶向 TNFRSF21/DR6/CD358。Anti-TNFRSF21/DR6/CD358 Antibody 带有 huIgG1 型重链和 huκ 型轻链,其预测的分子量 (MW) 为 150 kDa。Anti-TNFRSF21/DR6/CD358 Antibody 的同型对照可参考 Human IgG1 kappa, Isotype Control (HY-P99001)。
    Anti-TNFRSF21/DR6/CD358 Antibody
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.